earnings

Ernexa Therapeutics advances ERNA-101 toward Q3 IND filing

VolitionRx reports 300% Q1 revenue growth, nears vet milestone

Shares of billionaire Gautam Adani’s group companies have erased all losses triggered by a scathing short-seller report in 2023, as the conglomerate overcomes regulatory challenges.

Investors must purchase Zydus Lifesciences shares by Wednesday, May 27, to be eligible for the Rs 1,100 crore buyback, as the record date is May 29. The company approved buying back up to 95.65 lakh shares at Rs 1,150 each, a 7% premium. This follows strong Q4 results and a dividend recommendation.

Goldman lifts S&P 500 target to 8,000 on robust earnings growth

Foreign investors have pulled back from Indian stocks due to global uncertainty and high valuations, withdrawing $5 billion in early 2026. Despite this, analysts assure that India's long-term growth prospects remain strong. Currency stabilization is seen as key to their return, while domestic invest

Gold edges lower as traders gauge fragile US-Iran truce; Fed outlook in focus Reuters

ONGC shares fell as much as 4% on Wednesday despite the state-run explorer reporting a 46% YoY rise in consolidated Q4 net profit to Rs 10,820 crore. Revenue from operations grew 4% to Rs 1,73,805 crore, while standalone FY26 profit stood at Rs 32,894 crore. The company also highlighted strong perfo

Whitestone earnings missed by $0.01, revenue fell short of estimates

Nexalin Technology earnings beat, revenue fell short of estimates